Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
Cardiovascular
Immunology
Neuroscience
Oncology
Leqvio® - siRNA (regulation of LDL-C)
NCT05030428 VICTORION-2P (CKJX839B12302)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Secondary prevention of cardiovascular events in patients with elevated
levels of LDL-C
Phase 3
15000
1. Time to First Occurrence of 3P-MACE (3-Point Major Adverse
Cardiovascular Events)
Arm 1: Experimental Inclisiran sodium, Subcutaneous injection
Arm 2: Placebo Comparator, Placebo Subcutaneous injection
Participants with established cardiovascular disease (CVD)
Target
Patients
Read-out
2027
Milestone(s)
Publication
TBD
References
Abbreviations
Other
49 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation